Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSV-2 DNA vaccine
- Development stage
- Phase 2
- Lead developer
- Vical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
The HSV-2 DNA vaccine is a therapeutic DNA vaccine developed through a collaboration between Vical Incorporated and the University of Washington School of Medicine. It is designed for individuals already infected with herpes simplex virus type 2 (HSV-2) with the goal of reducing or eliminating periodic viral flare-ups, viral shedding, and transmission. The vaccine utilizes Vical’s proprietary Vaxfectin® adjuvant to enhance its immune-stimulating properties.
02
Targets
HSV DNA pol (Herpes simplex virus DNA polymerase)
Beyond the preview
Go deeper on HSV-2 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSV-2 DNA vaccine.